Lymphoma

Adverse physical functions were indicative of reduced survival and increased risk of ICANS in patients with non-Hodgkin lymphoma who were previously treated with CAR T-cell therapy.

Davide Rossi, MD, spoke about the impact of the MZL workshop and his hopes for the future of treatment and medicine in MZL.

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

The safety profile of ibrutinib/venetoclax in the phase 3 SYMPATICO trial was consistent with the known profiles for each individual agent.

As MZL is such a rare subtype of lymphoma, it can be hard to find or begin trials geared specifically toward this population.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

The toxicity profile of loncastuximab tesirine plus rituximab was consistent with prior clinical trials assessing each agent as monotherapy.

Potential contributing factors of marginal zone lymphoma (MZL) were highlighted in a recent discussion with James R. Cerhan, MD, PhD.

Anakinra prophylaxis did not significantly decrease the incidence or severity of CRS or ICANS in patients with LBCL treated with liso-cel.

Juan Alderuccio, MD, discussed treatment strategies for MZL, particularly as they relate to quality of life, and the role of prognosis models on treatment.

Julie M. Vose, MD, MBA, answered questions about the significance and potential impact of MZL Workshop.

Data from the ECHELON-3 trial support the approval of the brentuximab vedotin combo in relapsed/refractory B-cell lymphoma.

A pathologist discusses the challenges of diagnosing nodal MZL, including its lack of specific defining characteristics.

In the phase 2 TRANSCEND FL trial, lisocabtagene maraleucel met its primary end point of overall response rate in patients with marginal zone lymphoma.

Marginal Zone Lymphoma experts discussed recent advancements in all areas of MZL, while calling attention to gaps in knowledge in the 2024 MZL Scientific Workshop.

Completion of the phase 1 first-in-human trial revealed that iPSC-derived CAR natural killer cell therapy has potential for development across oncology.

Thomas Habermann, MD, discusses the significance of the MZL Workshop and its contributions to advancing research and improving outcomes.

Julie M. Vose, MD, MBA, discussed MZL research and future directions in the February Letter to Readers.

The TRANSCEND FL trial showed that liso-cel elicited an ORR of 97.1% and a complete response rate of 94.2% in patients with follicular lymphoma.

Researchers from the University of Wisconsin, Cornell, and a consortium of other institutions conducted a retrospective analysis on CD19-directed CAR T-cell therapy for R/R T-cell/histiocyte-rich LBCL.

Select patients may be eligible to continue treatment with tabelecleucel or ATA3219 in accordance with study protocols.

The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.

Brentuximab vedotin, lenalidomide, and rituximab yielded a median OS of 13.8 months and a median PFS of 4.2 months in the phase 3 ECHELON-3 trial.

The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.

Brad S. Kahl, MD, and Tycel Phillips, MD, discussed the use of acalabrutinib plus bendamustine and rituximab for patients with untreated MCL.